Epsilogen Ltd

About

Epsilogen Ltd is a clinical-stage biotechnology company focused on developing antibody therapies for cancer treatment. Founded in 2017 as a spin-out from King’s College London, Epsilogen specializes in immunoglobulin IgE, IgA, and IgG-based therapies, with a primary emphasis on IgE antibodies that target solid tumors. The company leverages expertise in IgE therapeutics, pioneered by Professor Sophia Karagiannis, and has secured significant funding, including a £30.75 million Series B financing in 2023. Epsilogen's lead clinical candidate, MOv18 IgE, is the world's first therapeutic IgE antibody designed to target folate receptor alpha on ovarian cancer cells. It has successfully completed a Phase I trial and is currently advancing to a Phase Ib study. Additionally, the company has developed the IGEG™ Platform, which combines IgE and IgG elements to create innovative bispecific-like antibodies aimed at enhancing oncology functionality. Epsilogen is headquartered in London and remains active in research and development within the biotechnology sector.